Novelty Nobility, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Phase 1
Recruiting
- Conditions
- Gastrointestinal Stromal TumorsSmall-cell Lung CancerAdenoid Cystic CarcinomaUveal MelanomaNeuroendocrine TumorsChromophobe Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Novelty Nobility, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT06805825
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Virginia, Fairfax, Virginia, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
© Copyright 2025. All Rights Reserved by MedPath